Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 2 | 2021 | 87 | 1.380 |
Why?
|
| Myasthenia Gravis | 2 | 2021 | 106 | 1.370 |
Why?
|
| Patient Preference | 1 | 2024 | 229 | 0.770 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2021 | 38 | 0.760 |
Why?
|
| Rehabilitation Centers | 3 | 2020 | 72 | 0.750 |
Why?
|
| Fitness Trackers | 1 | 2020 | 20 | 0.730 |
Why?
|
| Neoplasms | 11 | 2024 | 15927 | 0.680 |
Why?
|
| Telemedicine | 1 | 2024 | 552 | 0.570 |
Why?
|
| Cancer Survivors | 1 | 2021 | 742 | 0.440 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 376 | 0.410 |
Why?
|
| Hospitalization | 3 | 2023 | 2167 | 0.400 |
Why?
|
| Immunotherapy | 2 | 2021 | 3557 | 0.360 |
Why?
|
| Inpatients | 4 | 2023 | 683 | 0.300 |
Why?
|
| Motivation | 2 | 2021 | 516 | 0.290 |
Why?
|
| Exercise | 3 | 2021 | 1184 | 0.240 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 411 | 0.240 |
Why?
|
| Fatigue | 2 | 2021 | 1275 | 0.240 |
Why?
|
| Sports Medicine | 1 | 2021 | 30 | 0.190 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2021 | 48 | 0.180 |
Why?
|
| Sports | 1 | 2021 | 72 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2021 | 114 | 0.160 |
Why?
|
| Rehabilitation | 1 | 2019 | 36 | 0.160 |
Why?
|
| Perception | 1 | 2020 | 349 | 0.150 |
Why?
|
| Levorphanol | 1 | 2018 | 16 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2020 | 539 | 0.150 |
Why?
|
| Pain Management | 1 | 2024 | 712 | 0.150 |
Why?
|
| Recovery of Function | 2 | 2020 | 681 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2021 | 13414 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2024 | 39890 | 0.150 |
Why?
|
| Humans | 18 | 2024 | 270740 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 163 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 73333 | 0.140 |
Why?
|
| Disability Evaluation | 1 | 2017 | 234 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 473 | 0.130 |
Why?
|
| Pain, Intractable | 1 | 2018 | 180 | 0.130 |
Why?
|
| Self Care | 1 | 2017 | 246 | 0.130 |
Why?
|
| Pain | 1 | 2024 | 1694 | 0.130 |
Why?
|
| Male | 8 | 2024 | 128315 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 861 | 0.120 |
Why?
|
| Female | 10 | 2024 | 148940 | 0.120 |
Why?
|
| Adult | 5 | 2024 | 82040 | 0.120 |
Why?
|
| Age Factors | 1 | 2024 | 5457 | 0.120 |
Why?
|
| Neuralgia | 1 | 2018 | 265 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 1286 | 0.110 |
Why?
|
| Cancer Pain | 1 | 2018 | 345 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 901 | 0.100 |
Why?
|
| Curriculum | 1 | 2018 | 919 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5923 | 0.090 |
Why?
|
| Middle Aged | 4 | 2024 | 90352 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 2007 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1468 | 0.070 |
Why?
|
| Palliative Care | 1 | 2018 | 2178 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2023 | 931 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 4958 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5595 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2002 | 128 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2002 | 222 | 0.050 |
Why?
|
| Dwarfism | 1 | 2002 | 110 | 0.050 |
Why?
|
| Carcinogens | 1 | 2002 | 390 | 0.050 |
Why?
|
| Tendons | 1 | 2021 | 74 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 30998 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2021 | 273 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 110 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 550 | 0.040 |
Why?
|
| United States | 3 | 2021 | 15861 | 0.040 |
Why?
|
| Humerus | 1 | 2018 | 53 | 0.040 |
Why?
|
| Specialization | 1 | 2018 | 128 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 1106 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 698 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2021 | 764 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 1016 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 670 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4492 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2019 | 1325 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2018 | 950 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2904 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 118 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 22505 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 1133 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 631 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 1056 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 33737 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 16689 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 699 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 6441 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 16215 | 0.010 |
Why?
|
| Animals | 1 | 2002 | 61956 | 0.000 |
Why?
|